Recursion Pharmaceuticals, Inc.
RXRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001601830
In the last 90 days, Recursion Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 4 sales; 344 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; ARK Invest is the only superinvestor holding it.
13F holders, Q2 2024
Institutional positions in Recursion Pharmaceuticals, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 270
- +24 vs. Q1 2024
- Shares held
- 251.9M
- +40.9M (+19.4%) vs. Q1 2024
- Total value
- $1.89B
- −$213.9M (−10.2%) vs. Q1 2024
- New holders
- 70
- 110 more added
- Sold out
- 46
- 48 more reduced
2 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RXRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 344 | $1.33B |
| Q1 2026 | 335 | $1.03B |
| Q4 2025 | 335 | $1.33B |
| Q3 2025 | 322 | $1.58B |
| Q2 2025 | 333 | $1.57B |
| Q1 2025 | 337 | $1.63B |
| Q4 2024 | 316 | $2.06B |
| Q3 2024 | 268 | $1.74B |
| Q2 2024 | 270 | $1.89B |
| Q1 2024 | 248 | $2.12B |
| Q4 2023 | 199 | $2.04B |
| Q3 2023 | 192 | $1.16B |
| Q2 2023 | 158 | $952.8M |
| Q1 2023 | 159 | $841.4M |
| Q4 2022 | 144 | $954.0M |
| Q3 2022 | 146 | $1.21B |
| Q2 2022 | 133 | $861.1M |
| Q1 2022 | 128 | $680.3M |
| Q4 2021 | 126 | $1.62B |
| Q3 2021 | 84 | $1.26B |
| Q2 2021 | 75 | $1.71B |
| Q1 2021 | 1 | $1.00K |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Recursion Pharmaceuticals, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Millennium Management LLC | 0 | $0 | 0.00% | −11,077−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −10,110−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −9,000−100.0% | Sold out |
| Baldwin Brothers Inc | 0 | $0 | 0.00% | −7,336−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −7,290−100.0% | Sold out |
| Tucker Asset Management LLC | 0 | $0 | 0.00% | −3,091−100.0% | Sold out |
| Smithfield Trust Co | 0 | $0 | 0.00% | −1,099−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −789−100.0% | Sold out |
| Capital Advisors, Ltd. LLC | 0 | $0 | 0.00% | −704−100.0% | Sold out |
| Sandy Spring Bank | 0 | $0 | 0.00% | −650−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −314−100.0% | Sold out |
| First Command Advisory Services, Inc. | 0 | $0 | 0.00% | −70−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −28−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −26−100.0% | Sold out |
| Sofos Investments, Inc. | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Householder Group Estate & Retirement Specialist, LLC | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Credit Suisse AG | – | – | – | – | Not filed |
| RIA Advisory Group LLC | – | – | – | – | Not filed |